西安市结核病患者耐药情况及耐药菌株基因突变现状

doi:10.12183/j.scjpm.2022.1464

摘要/Abstract

摘要： 目的了解西安市结核病患者耐药情况,以及对常用抗结核药耐药的结核分枝杆菌（MTB）的相关耐药基因突变特征进行分析。方法对2020年1—12月西安市结核病定点医院上报的痰涂片阳性结核病患者的痰样本进行分离培养,对鉴定为MTB阳性的菌株样本进行药敏试验,并利用全基因组测序（WGS）对耐药菌株的耐药相关基因突变特征进行分析。结果共鉴定出892例MTB阳性患者,其中初治患者758例,复治患者134例;耐药209例,总耐药率23.43%;单耐药（MR-TB）、多耐药（PDR-TB）、耐多药（MDR-TB）、广泛耐药（XDR-TB）和利福平耐药（RR-TB）率分别为10.43%、2.47%、4.60%、0.45%和6.28%。复治患者的耐药率（31.34%）明显高于初治患者（22.03%）;且2组耐药患者MR-TB、PDR-TB、MDR-TB、XDR-TB和RR-TB所占比例的差异均有统计学意义（均P<0.05）。209例MTB耐药菌株对常用抗结核药品的耐药相关基因突变主要为81株katG（77.14%,异烟肼）、54株rpoB（96.43%,利福平）、49株rpsL（84.48%,链霉素）、24株embB（88.89%,乙胺丁醇）、17株pncA（89.47%,吡嗪酰胺）、10株gyrA（90.91%,氧氟沙星）、18株rss（94.74%,二线注射类抗结核药物）。其中相关耐药基因突变位点频率最高的分别为katG S315T（72株）、rpsL K43R（42株）、rss A1401G（23株）、rpoB S531L（19株）、embB M306V（13株）和rpoB H526D（11株）。结论西安市结核病患者对常用抗结核药具有较高的耐药性,耐药菌株基因突变以katG、rpoB、rpsL、embB和pncA等基因突变为主,且主要发生在katG S315T、rpsL K43R等高频突变位点,针对上述突变特征开发敏感、特异的快速分子检测方法具有理论可行性。

关键词: 结核病, 结核分枝杆菌, 耐药, 全基因组测序, 基因突变

Abstract: Objective To understand the drug resistance of tuberculosis patients in Xi'an, and to analyze the mutation characteristics of drug-resistant genes related to Mycobacterium tuberculosis （MTB） that are resistant to commonly anti-tuberculosis drugs. Methods The sputum samples of tuberculosis patients with positive sputum smears reported by tuberculosis-designated hospitals in Xi'an from January to December 2020 were isolated and cultured, and the samples identified as MTB-positive strains were tested for drug sensitivity, and the mutation characteristics of drug-resistant related genes of drug-resistant strains were analyzed by whole genome sequencing （WGS）. Results A total of 892 MTB-positive patients were identified, including 758 newly treated patients and 134 retreated patients; 209 cases were drug-resistant, and the total drug resistance rate was 23.43%; The rates of monodrug resistant tuberculosis （MR-TB）, poly-drug resistant tuberculosis （PDR-TB）, multidrug-resistant tuberculosis （MDR-TB）, extensive drug-resistant tuberculosis （XDR-TB）, and rifampicin-resistant tuberculosis （RR-TB） were 10.43%, 2.47%, 4.60%, 0.45%, and 6.28%, respectively. The drug resistance rate of retreated patients （31.34%） was significantly higher than that of newly treated patients （22.03%）; The proportion of MR-TB, PDR-TB, MDR-TB, XDR-TB, and RR-TB in drug-resistant patients of the two groups was statistically significant （all P<0.05）. Among 209 MTB-resistant strains, the mutations of resistance-related genes to commonly used anti-tuberculosis drugs were 81 strains of katG （77.14%, isoniazid）, 54 strains of rpoB （96.43%, rifampicin）, 49 strains of rpsL （84.48%, streptomycin）, 24 strains of embB （88.89%, ethambutol）, 17 strains of pncA （89.47%, pyrazinamide）, 10 strains of gyrA （90.91%, ofloxacin）, and 18 strains of rss （94.74%, second-line injection type anti-tuberculosis drugs）. Among them, katG S315T （72 strains）, rpsL K43R （42 strains）, rss A1401G （23 strains）, rpoB S531L （19 strains）, embB M306V （13 strains）, and rpoB H526D （11 strains） had the highest mutation frequency of related drug resistance genes. Conclusions Tuberculosis patients in Xi'an are highly resistant to commonly used anti-tuberculosis drugs. The gene mutations of drug-resistant strains are mainly katG, rpoB, rpsL, embB, and pncA, and mainly occur at high-frequency mutation sites such as katG S315T and rpsL K43R. It is theoretically feasible to develop sensitive and specific rapid molecular detection methods based on the above mutation characteristics.

Key words: Tuberculosis, Mycobacterium tuberculosis, Drug resistance, Whole genome sequencing, Gene mutation

中图分类号:

许娟, 闫涛涛, 侯静涛, 杜粉静, 张宁. 西安市结核病患者耐药情况及耐药菌株基因突变现状[J]. 华南预防医学, 2022, 48(12): 1464-1469.

XU Juan, YAN Tao-tao, HOU Jing-tao, DU Fen-jing, ZHANG Ning. Drug resistance of tuberculosis patients and gene mutation of drug-resistant strains in Xi'an[J]. South China Journal of Preventive Medicine, 2022, 48(12): 1464-1469.

参考文献

[1] World Health Organization.Global tuberculosis report 2021[R]. Geneva: World Health Organization, 2021:4-7.
[2] Zhou Y, Anthony R, Wang S, et al.The epidemic of multidrug resistant tuberculosis in China in historical and phylogenetic perspectives[J]. J Infect, 2020, 80(4): 444-453.
[3] World Health Organization.Global tuberculosis report 2020[R]. Geneva: World Health Organization, 2020: 6-7.
[4] 赵雁林, 逄宇. 结核病实验室检验规程[M]. 北京:人民卫生出版社, 2015: 1-260.
[5] 中国防痨协会. 耐药结核病化学治疗指南(2019年简版)[J]. 中国防痨杂志, 2019, 41(10): 1025-1073.
[6] 王晓君, 李月华, 易凤莲, 等. 1990—2017年中国结核病流行与控制情况[J]. 中华流行病学杂志, 2020, 41(6): 856-860.
[7] 全国第五次结核病流行病学抽样技术指导组. 2010年全国第五次结核病流行病学抽样调查报告[J]. 中国防痨杂志,2012,34(8):485-508.
[8] 杨健, 张天华, 鲜小萍, 等. 西安市218株结核分枝杆菌耐药情况分析[J]. 检验医学, 2019, 34(5):421-427.
[9] 杨翰,程悦,马怀芬,等. 2018—2020年西安市耐药结核病的流行现状及新冠疫情防控对其的影响[J]. 西安交通大学学报(医学版),2021,42(4):562-568.
[10] 马进宝, 任斐, 曾令城, 等. 2015—2019年西安市680例耐多药结核病患者耐药情况分析[J]. 中国防痨杂志, 2020, 42(6):609-613.
[11] 田丽, 周伟, 黄星, 等. 中国异烟肼耐药结核分枝杆菌基因突变特征分析[J]. 中国防痨杂志, 2022, 44(4):354-361.
[12] 李丽, 孟繁荣, 刘志辉. 中国利福平耐药结核分枝杆菌株rpoB基因耐药决定区基因突变的分子特征[J]. 实用医学杂志, 2015, 31(14):2372-2375.
[13] 罗丹, 覃慧芳, 叶婧, 等. 广西壮族自治区结核分枝杆菌耐药基因突变特征及其与基因型的相关性分析[J]. 中国防痨杂志, 2021, 43(6):596-601.
[14] 高敏, 杨婷婷, 李桂莲, 等. 基于全基因组测序的我国耐多药结核分枝杆菌耐药突变特征分析[J]. 中华流行病学杂志, 2020, 41(5):770-775.
[15] Pang Y, Zhu D, Zheng H, et al.Prevalence and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates from Southern China[J]. BMC Infect Dis, 2017, 17(1): 1-8.
[16] Li Q, Wang Y, Li Y, et al.Characterisation of drug resistance-associated mutations among clinical multidrug-resistant Mycobacterium tuberculosis isolates from Hebei Province, China[J]. J Glob Antimicrob Resist, 2019, 18: 168-176.
[17] 张洁,杨新宇,潘丽萍,等北京市复治结核病患者非北京基因型菌株谱系及耐药分析[J].中国热带医学,2022,22(5):395-399.